Skandinaviska Enskilda Banken Ab (Publ) Sage Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$37.06 - $47.11 $467,252 - $593,962	-12,608 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$40.26 - $57.37 $2.7 Million - $3.85 Million	-67,100 Reduced 84.18%	12,608 $559,000
Q2 2021 Aug 10, 2021	BUY	$54.88 - $79.29 $1.03 Million - $1.48 Million	18,700 Added 30.65%	79,708 $4.53 Million
Q1 2021 May 14, 2021	BUY	$70.65 - $96.76 $4.16 Million - $5.7 Million	58,908 Added 2805.14%	61,008 $4.57 Million
Q4 2020 Feb 11, 2021	BUY	$58.41 - $89.06 $122,661 - $187,026	2,100 New	2,100 $182,000
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $271,458 - $412,170	-6,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $171,270 - $284,790	6,600 New	6,600 $274,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.